Andreas Bruederle,Padraig Moran,Anastasios Stathis
申请号：
US14365793
公开号：
US20140335109A1
申请日:
2012.12.04
申请国别(地区):
US
年份:
2014
代理人:
摘要：
The present invention relates to a therapeutic method for the treatment of cancer that comprises the use of a combination of inotuzumab ozogamicin (CMC-544) and temsirolimus. The enhanced antitumor of the combination therapy is particularly useful for patient population that are recalcitrant to inotuzumab ozogamicin or temsirolimus therapy, relapse after treatment with inotuzumab ozogamicin or temsirolimus or where enhanced antitumor effect reduces toxicities associated with treatment using inotuzumab ozogamicin or temsirolimus.
